Ken Griffin Novo Cure LTD Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Cure LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 167,300 shares of NVCR stock, worth $2.82 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
167,300
Previous 132,800
25.98%
Holding current value
$2.82 Million
Previous $2.27 Million
14.95%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding NVCR
# of Institutions
262Shares Held
77MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$205 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$200 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$134 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$72.6 Million0.01% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$51.1 Million12.67% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.77B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...